Regional anti-MSLN CAR T delivery is also being used by the Sadelain team at Memorial Sloane Kettering Cancer Center (MSKCC) in a phase I/II trial against MM (NCT02414269), based on the success of the same approach in an orthotopic mouse model [26]. Here, MSLN is linked to Miyoshi myopathy.